Clinical research progresss of antiviral drugs for the novel coronavirus pneumonia
10.3760/cma.j.cn112866-2020213-00020
- VernacularTitle: 新型冠状病毒肺炎抗病毒药物临床研究进展
- Author:
Weigang WU
1
;
Guilin YANG
1
;
Xiaobin ZENG
1
;
Shipin WU
1
;
Boping ZHOU
1
Author Information
1. Department of Infectious Disease,Shenzhen People’s Hospital,Second Clinical Medical College of Jinan University,and the First Affiliated Hospital of Southern University of Science and Technology,Shenzhen 518020,China
- Publication Type:Review
- Keywords:
Novel coronavirus;
Pneumonia;
Antivirus;
Drugs
- From:
Chinese Journal of Experimental and Clinical Virology
2020;34(0):E001-E001
- CountryChina
- Language:Chinese
-
Abstract:
The novel coronavirus (2019-nCoV or SARS-CoV-2) is a highly contagious and deadly virus that has infected more than 50 000 people and killed more than 1 000 people in 25 countries around the world. People who infected by the novel coronavirus may suffer from fever and cough, some may gradually appear breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death. However, there are no definite and effective antiviral drugs for the novel coronavirus pneumonia all around the world. Therefore, this article aims to provide new idea for the effective treatment of the novel coronavirus pneumonia by summarizing the basic research and clinical progress of antiviral drugs at home and abroad.
